Logo

SNSE

Sensei Biotherapeutics, Inc.

SNSE

Sensei Biotherapeutics, Inc. • NASDAQ
$8.42 ▼ -0.36% (-0.03)
Market Cap $10.62 M
52w High $18.35
52w Low $5.00
Dividend Yield 0%
P/E -0.44
Volume 5.18K
Outstanding Shares 1.26M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $-4.851M ▼ $4.851M ▼ $-4.569M ▲ 94.187% ▲ $-3.62 ▲ $-4.529M ▲
Q2-2025 $0 $5.169M ▼ $-4.936M ▲ 0% $-3.91 ▼ $-4.889M ▲
Q1-2025 $0 $7.244M ▲ $-6.864M ▲ 0% $-0.27 ▲ $-6.821M ▲
Q4-2024 $0 $7.184M ▼ $-7.77M ▼ 0% $-0.31 ▼ $-7.614M ▼
Q3-2024 $0 $7.683M $-7.253M 0% $-0.29 $-7.092M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $25.041M ▼ $27.589M ▼ $4.582M ▲ $23.007M ▼
Q2-2025 $28.628M ▼ $31.783M ▼ $4.469M ▼ $27.314M ▼
Q1-2025 $34.331M ▼ $38.273M ▼ $6.286M ▼ $31.987M ▼
Q4-2024 $41.335M ▼ $45.361M ▼ $6.975M ▼ $38.386M ▼
Q3-2024 $47.001M $53.254M $7.475M $45.779M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.568M ▲ $-3.586M ▲ $1.743M ▼ $-152K ▲ $-1.995M ▼ $-3.586M ▲
Q2-2025 $-4.936M ▲ $-5.909M ▲ $8.757M ▲ $-168K ▲ $2.68M ▲ $-5.925M ▲
Q1-2025 $-6.864M ▲ $-7.094M ▼ $7.191M ▲ $-214K ▼ $-117K ▲ $-7.094M ▼
Q4-2024 $-7.77M ▼ $-5.792M ▼ $-3.151M ▼ $-194K ▲ $-9.137M ▼ $-5.792M ▼
Q3-2024 $-7.253M $-5.47M $12.914M $-204K $7.24M $-5.47M

Five-Year Company Overview

Income Statement

Income Statement Sensei is a classic early‑stage biotech: it has had essentially no product or collaboration revenue over the past several years, so its income statement is all cost and no income. The company has reported steady operating losses each year, driven mainly by research, development, and basic corporate overhead. Losses per share have been sizable and, at times, have worsened as the company ramped development, then improved slightly as spending was trimmed back. Overall, the pattern is consistent: a business still in the “investment phase,” with no commercial engine to offset its ongoing expenses.

Balance Sheet

Balance Sheet The balance sheet is small and fairly simple. Assets are modest and consist largely of cash and equivalents, with very little in physical or long‑lived assets. Shareholders’ equity has declined over time as repeated losses have eaten into the capital base. On the positive side, the company carries little to no financial debt, which reduces interest burdens and default risk. On the negative side, the equity cushion is thin, meaning there is limited room to keep funding losses without raising new capital or doing a major strategic deal. Taken together, the balance sheet is clean but light, and it does not support a long runway on its own.

Cash Flow

Cash Flow Cash flows tell the same story as the income statement. Operating cash flow has been consistently negative, reflecting the reality that research and corporate costs are paid out in cash while no revenue comes in. Free cash flow is also negative, although the company has not been spending heavily on equipment or facilities, which is typical for a science‑ and IP‑focused biotech. The cash burn looks modest in absolute terms but is meaningful relative to the cash on hand, which explains workforce reductions and the push to explore strategic alternatives. Future spending capacity is tightly linked to the outcome of those strategic decisions or to potential outside funding.

Competitive Edge

Competitive Edge Sensei’s original competitive pitch was its tumor‑microenvironment‑activated antibody platform, aimed at making cancer therapies more selective and less toxic. That idea offered a clear scientific angle in a crowded oncology landscape. However, shelving the lead drug candidate greatly weakens its competitive standing, because there is no longer a clear flagship program proving the platform in patients. Meanwhile, the broader immuno‑oncology space is dominated by larger companies with many trials and broader pipelines. At this point, Sensei’s competitive position is less about being an active clinical player and more about being an owner of niche technology and intellectual property that could be more valuable in the hands of a larger partner or acquirer than on a standalone basis.

Innovation and R&D

Innovation and R&D The company’s main innovation, the TMAb platform, is designed to switch antibodies “on” only in the acidic environment of tumors, which could in theory make treatments both safer and more effective. The targets it chose—such as VISTA, VSIG4, and CD39—sit at important control points in the immune system, so the scientific rationale is solid. That said, the decision to stop developing the lead candidate shows how fragile early‑stage drug development can be: strong concepts still need clear data and sustained funding. With the pipeline now largely preclinical and the company in strategic review, internal R&D momentum has slowed, and the future of these programs likely depends on whether a stronger, better‑funded organization decides to license or acquire them.

Summary

Sensei Biotherapeutics is a pre‑revenue, clinical‑stage biotech that has consistently spent cash on research while generating no commercial income. Its balance sheet is straightforward, with modest cash reserves, minimal hard assets, and little debt, but also a shrinking equity base that limits how long it can absorb losses without outside support. Cash burn has been steady, prompting cost cuts and a search for strategic alternatives. Competitively, the firm once leaned on a differentiated immuno‑oncology platform, but the halt of its lead program leaves its technology unproven in later‑stage trials and its pipeline effectively in limbo. The core source of potential value now appears to be the TMAb technology and related intellectual property, rather than an active, advancing product portfolio. The company is at a turning point, with its future depending largely on the outcome of its strategic review and the level of interest from potential partners or acquirers, rather than on its current financial performance.

NEWS

November 14, 2025 · 7:30 AM UTC

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Read more

October 30, 2025 · 9:00 AM UTC

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Read more

October 17, 2025 · 8:00 AM UTC

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Read more

September 23, 2025 · 7:30 AM UTC

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Read more

September 3, 2025 · 8:00 AM UTC

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Read more